Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a single-center Phase I study to determine the maximum tolerated dose and safety of
Neihulizumab for the treatment of Minnesota standard-risk aGVHD. Patients undergoing
allogeneic transplant with either a myeloablative or non-myeloablative conditioning regimen,
and recipients of all donor sources will be enrolled to this trial.